Cellmid Limited ( ASX:CDY.AX ) is an Australian biotechnology company developing innovative new therapies and diagnostic tests for heart attack, inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. Midkine is a cytokine that promotes cell migration, growth and survival. Discovered over twenty years ago, midkine’s roles in inflammation and cell survival have been extensively validated by researchers worldwide. Elevated midkine concentration in the blood or other body fluids is strongly indicative of cancer. Cellmid’s first product is a blood test that sensitively and accurately measures serum midkine levels. As well as developing this test in-house, Cellmid is actively out-licensing its broad diagnostic patent portfolio for the early detection, monitoring, prognosis and disease monitoring of cancer. The Company’s most advanced clinical development program targets the treatment of heart attack (acute myocardial infarction or AMI) utilising the midkine protein and its anti-apoptotic characteristics. Cellmid is also humanising its lead anti-midkine antibody for the treatment of inflammatory and autoimmune disorders.

Bristol-Myers Squibb Company (NYSE: BMY ) Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to extend and enhance human life.

However, despite the growing need, there are currently no approved therapeutic treatments for NASH. Modification of risk factors, such as obesity and hyperlipidemia, and proper diabetic control is generally recommended for the treatment of NASH, and the standard of care includes lifestyle changes to promote weight loss, including low-calorie, low-fat diets and physical activity. Although weight loss can be potentially significant in delaying the progression of NASH, studies have shown that, for most individuals, it is generally very difficult to maintain over the long-term, even following bariatric surgery.

This study was supported in part by National Natural Science Foundation of China No. 81170047 and 81370151 (to D.G.); National Basic Research Program of China (973 Program, 2012CB124701) and Shenzhen overseas high-level talents innovation program No. YFZZ20111009 (to D.G.).

        Third, the FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that is expected to lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months.

        We have never declared or paid cash dividends on our common stock, and we do not expect to pay any cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.

Taxable income of Maltese companies is subject to tax at the rate of 35% in 2018 and 2017 (“Regular Tax Rate”).

Caruso, P. et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler. Thromb. Vasc. Biol. 30, 716–723 (2010).

Wang, Y. et al. QSYQ Attenuates Oxidative Stress and Apoptosis Induced Heart Remodeling Rats through Different Subtypes of NADPH-Oxidase. Evid Based Complement Alternat Med 2013, 824960, 10.1155/2013/824960 (2013).

NOTE: Richard Wurtman, mentioned in the articles, was also the developer of the “Fen” half of Fen-Phen, the miracle diet drug which became another disaster from unintended consequences. content.time.com /time/subscriber /article/0,33009,985187-4,00.html

Telomere Plus from enzymedica has been subjectively good for me. Cheaper not to buy it from their website (around 20 sterling from amazon). As for scientific evidence read this paper, ‘Identification_of_Telomerase-activating_Blends_From_Naturally_Occurring_Compounds’.

(A) Representative HCN4 current traces from cells that underwent cholesterol depletion by MβCD (red) or enrichment by MβCD/cholesterol (blue) were compared to control (black). (B) Current densities of HCN4 are reduced upon cholesterol depletion and unchanged with enrichment. (C) Steady-state activation was not affected by modification of membrane cholesterol content. (D,E) HCN4 channel activation can be fit by a dual-exponential function whose 2 components were unchanged compared to control. (F) The kinetics of HCN4 deactivation can be described by mono-exponential functions which were slowed with cholesterol depletion and enrichment. (n > 8; P < 0.05).